Dr Samuel Jones
Postdoctoral Research Associate
School of Pharmacy and Pharmaceutical Sciences
- JonesSR15@cardiff.ac.uk
- Redwood Building, Room Room 2.04, King Edward VII Avenue, Cardiff, CF10 3NB
Publication
2022
- Jones, S., Farr, G., Nimmanon, T., Ziliotto, S., Gee, J. M. and Taylor, K. M. 2022. The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer. Exploration of Targeted Anti-tumor Therapy 3, pp. 224-239. (10.37349/etat.2022.00080)
2020
- Kandil, S. B., Jones, S. R., Smith, S., Hiscox, S. E. and Westwell, A. D. 2020. Structure-based virtual screening, synthesis and biological evaluation of potential FAK-FAT domain inhibitors for treatment of metastatic cancer. Molecules 25(15), article number: 3488. (10.3390/molecules25153488)
2018
- Kandil, S., Prencipe, F., Jones, S., Hiscox, S. and Westwell, A. D. 2018. The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer. Chemical Biology and Drug Design 91(1), pp. 314-321. (10.1111/cbdd.13083)
2017
- Jones, S. R. 2017. Exploring Focal Adhesion Kinase (FAK) as a therapeutic target in triple negative breast cancer. PhD Thesis, Cardiff University.
Erthyglau
- Jones, S., Farr, G., Nimmanon, T., Ziliotto, S., Gee, J. M. and Taylor, K. M. 2022. The importance of targeting signalling mechanisms of the SLC39A family of zinc transporters to inhibit endocrine resistant breast cancer. Exploration of Targeted Anti-tumor Therapy 3, pp. 224-239. (10.37349/etat.2022.00080)
- Kandil, S. B., Jones, S. R., Smith, S., Hiscox, S. E. and Westwell, A. D. 2020. Structure-based virtual screening, synthesis and biological evaluation of potential FAK-FAT domain inhibitors for treatment of metastatic cancer. Molecules 25(15), article number: 3488. (10.3390/molecules25153488)
- Kandil, S., Prencipe, F., Jones, S., Hiscox, S. and Westwell, A. D. 2018. The discovery of new and more potent chloropyramine (C4) analogues for the potential treatment of invasive breast cancer. Chemical Biology and Drug Design 91(1), pp. 314-321. (10.1111/cbdd.13083)
Gosodiad
- Jones, S. R. 2017. Exploring Focal Adhesion Kinase (FAK) as a therapeutic target in triple negative breast cancer. PhD Thesis, Cardiff University.